No effect of acenocoumarol therapy on levels of endothelial activation markers in sickle cell disease

J. B. Schnog; M. R. Mac Gillavry; R. A. Rojer; J. C. M. Meijers; R. Fijnheer; H. ten Cate; D. P. M. Brandjes; A. J. Duits

doi:https://doi.org/10.1002/ajh.10178

No effect of acenocoumarol therapy on levels of endothelial activation markers in sickle cell disease

J. B. Schnog, M. R. Mac Gillavry, R. A. Rojer, J. C. M. Meijers, R. Fijnheer, H. ten Cate, D. P. M. Brandjes, A. J. Duits

Research output: Contribution to journal › Article › Academic › peer-review

8 Citations (Scopus)

Abstract

Sickle cell patients are characterized by a chronic inflammatory and hypercoagulable state, depicted by elevated levels of pro-inflammatory cytokines, endothelial adhesion molecules, and elevated markers of thrombin generation. We set out to determine whether anticoagulation with a coumadin derivative reduces inflammation in sickle cell disease. Therefore, serum levels of NFkappaB-regulated endothelial adhesion molecule soluble vascular cell adhesion molecule-1 and serum levels of non-NFkappaB-dependent markers of endothelial activation (soluble cellular fibronectin and von Willebrand factor antigen) were compared during treatment with acenocoumarol (INR 1.6-2.0) and placebo. No effect on circulating levels of the measured parameters was observed during treatment with acenocoumarol as compared to placebo. In the targeted INR range, anticoagulation of sickle cell patients with acenocoumarol does not seem to reduce endothelial activation. (C) 2002 Wiley-Liss, Inc

Original language	English
Pages (from-to)	53-55
Journal	American journal of hematology
Volume	71
Issue number	1
DOIs	https://doi.org/10.1002/ajh.10178
Publication status	Published - 2002

Access to Document

https://doi.org/10.1002/ajh.10178

Cite this

@article{7acb50c3de90421f9102f3dd8de1dd1b,

title = "No effect of acenocoumarol therapy on levels of endothelial activation markers in sickle cell disease",

abstract = "Sickle cell patients are characterized by a chronic inflammatory and hypercoagulable state, depicted by elevated levels of pro-inflammatory cytokines, endothelial adhesion molecules, and elevated markers of thrombin generation. We set out to determine whether anticoagulation with a coumadin derivative reduces inflammation in sickle cell disease. Therefore, serum levels of NFkappaB-regulated endothelial adhesion molecule soluble vascular cell adhesion molecule-1 and serum levels of non-NFkappaB-dependent markers of endothelial activation (soluble cellular fibronectin and von Willebrand factor antigen) were compared during treatment with acenocoumarol (INR 1.6-2.0) and placebo. No effect on circulating levels of the measured parameters was observed during treatment with acenocoumarol as compared to placebo. In the targeted INR range, anticoagulation of sickle cell patients with acenocoumarol does not seem to reduce endothelial activation. (C) 2002 Wiley-Liss, Inc",

author = "Schnog, {J. B.} and {Mac Gillavry}, {M. R.} and Rojer, {R. A.} and Meijers, {J. C. M.} and R. Fijnheer and {ten Cate}, H. and Brandjes, {D. P. M.} and Duits, {A. J.}",

year = "2002",

doi = "https://doi.org/10.1002/ajh.10178",

language = "English",

volume = "71",

pages = "53--55",

journal = "American journal of hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "1",

}

TY - JOUR

T1 - No effect of acenocoumarol therapy on levels of endothelial activation markers in sickle cell disease

AU - Schnog, J. B.

AU - Mac Gillavry, M. R.

AU - Rojer, R. A.

AU - Meijers, J. C. M.

AU - Fijnheer, R.

AU - ten Cate, H.

AU - Brandjes, D. P. M.

AU - Duits, A. J.

PY - 2002

Y1 - 2002

N2 - Sickle cell patients are characterized by a chronic inflammatory and hypercoagulable state, depicted by elevated levels of pro-inflammatory cytokines, endothelial adhesion molecules, and elevated markers of thrombin generation. We set out to determine whether anticoagulation with a coumadin derivative reduces inflammation in sickle cell disease. Therefore, serum levels of NFkappaB-regulated endothelial adhesion molecule soluble vascular cell adhesion molecule-1 and serum levels of non-NFkappaB-dependent markers of endothelial activation (soluble cellular fibronectin and von Willebrand factor antigen) were compared during treatment with acenocoumarol (INR 1.6-2.0) and placebo. No effect on circulating levels of the measured parameters was observed during treatment with acenocoumarol as compared to placebo. In the targeted INR range, anticoagulation of sickle cell patients with acenocoumarol does not seem to reduce endothelial activation. (C) 2002 Wiley-Liss, Inc

AB - Sickle cell patients are characterized by a chronic inflammatory and hypercoagulable state, depicted by elevated levels of pro-inflammatory cytokines, endothelial adhesion molecules, and elevated markers of thrombin generation. We set out to determine whether anticoagulation with a coumadin derivative reduces inflammation in sickle cell disease. Therefore, serum levels of NFkappaB-regulated endothelial adhesion molecule soluble vascular cell adhesion molecule-1 and serum levels of non-NFkappaB-dependent markers of endothelial activation (soluble cellular fibronectin and von Willebrand factor antigen) were compared during treatment with acenocoumarol (INR 1.6-2.0) and placebo. No effect on circulating levels of the measured parameters was observed during treatment with acenocoumarol as compared to placebo. In the targeted INR range, anticoagulation of sickle cell patients with acenocoumarol does not seem to reduce endothelial activation. (C) 2002 Wiley-Liss, Inc

U2 - https://doi.org/10.1002/ajh.10178

DO - https://doi.org/10.1002/ajh.10178

M3 - Article

C2 - 12221677

SN - 0361-8609

VL - 71

SP - 53

EP - 55

JO - American journal of hematology

JF - American journal of hematology

IS - 1

ER -